Full-Time

Vice President Head of Epilepsy

R&D

Updated on 9/3/2026

Jazz Pharmaceuticals

Jazz Pharmaceuticals

1,001-5,000 employees

Biopharmaceuticals focused on neuroscience and oncology

Compensation Overview

$445k - $506k/yr

Remote in USA + 2 more

More locations: Pennsylvania, USA | California, USA

Remote

Remote role with travel of up to 10%–20% of the time.

PhD, MD

Category
Biology & Biotech

Get referred to Jazz Pharmaceuticals

See people who can refer or advise you

Requirements
  • MD and PhD with specialization in Epilepsy.
  • Board Certification in Neurology or subspecialties.
  • A minimum of 10 years of experience in drug development in both academia and the pharmaceutical industry.
  • National or international recognition as an academic epileptologist and/or epilepsy drug developer.
  • Significant experience in clinical research and trial leadership and investigator-initiated studies.
  • A strong track record of publications, conference presentations, and scientific leadership roles.
  • An established network across academic centers, clinical trial sites, and epilepsy organizations.
  • Proven experience leading and developing teams in a global matrixed organization.
  • The ability to proactively lead through change and ambiguity.
  • The ability to effectively communicate complex ideas concisely with impact within executive-level forums.
  • The ability to effectively lead cross-functional teams and successfully leverage internal and external partnerships.
  • Excellent organizational and time management skills, with the ability to lead and represent department functions on project teams in a matrix organization.
  • Excellent verbal and written communication skills with collaborative interpersonal skills.
  • The ability to travel up to 10%–20% of the time.
Responsibilities
  • Develop and shape epilepsy clinical development strategy aligned with the portfolio, regulatory expectations, and unmet needs.
  • Define clinical endpoints, trial designs, and patient populations across epilepsy development programs.
  • Integrate scientific insights, literature, and competitive intelligence into actionable program strategies.
  • Steward epilepsy programs through governance to align budget and timeline expectations.
  • Execute multiple epilepsy programs according to budget and timeline.
  • Serve as the accountable R&D leader for the Jazz Scientific Advisory Board in Epilepsy.
  • Serve as a leading external scientific voice by building trusted relationships with epilepsy experts and stakeholders.
  • Engage academic epileptologists and experts to inform strategy, evidence generation, and trial design.
  • Represent the company at congresses, symposia, and regulatory interactions as an epilepsy clinical expert.
  • Drive collaborative research initiatives with academic institutions and external partners advancing epilepsy science.
  • Establish and oversee collaborative research aligned with strategic priorities.
  • Identify emerging scientific opportunities and innovative technologies to advance epilepsy therapeutic development.
  • Bridge preclinical discoveries and clinical development to enhance the probability of success for epilepsy programs.
  • Translate mechanistic insights and biomarkers into clinical hypotheses, endpoints, and decision frameworks.
  • Partner with nonclinical teams to refine target validation and support translational development strategies.
  • Provide R&D leadership at enterprise-wide epilepsy forums to advance the epilepsy pipeline, commercial portfolio, and category leadership.
  • Influence Executive Committee and Board stakeholders through clear, data-rich scientific presentations.
  • Mentor internal teams and contribute to capability building in epilepsy expertise across the organization.
  • Embed patient and caregiver perspectives into development strategy through meaningful community engagement.
  • Partner with advocacy organizations and patients to incorporate patient-centricity into trial design and endpoint selection.
  • Ensure development programs reflect diversity, access considerations, and real-world patient priorities.
  • Manage and develop high-performing teams in a global organization.
  • Build leadership capability through mentoring, coaching, and talent development programs to enhance performance and engagement.
  • Foster a learning culture featuring innovation and operational excellence.
  • Lead through change while building trust and credibility across the enterprise.

Jazz Pharmaceuticals develops and markets therapies in neuroscience and oncology. Its products include Xyrem and the lower-sodium option Xywav for narcolepsy, Epidiolex for seizures in severe epilepsy, and oncology medicines Zepzelca for small cell lung cancer and Vyxeos for AML, with Epidiolex being cannabidiol-based. The company grows its portfolio through a mix of in-house R&D and strategic acquisitions that broaden its specialty-drug lineup and global reach. Its goal is to expand approved treatments and the pipeline to help patients with limited options by building a diversified, specialty-focused portfolio.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dublin, Ireland

Founded

2003

Get referred to Jazz Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Second-quarter 2026 revenue reached $1.21 billion, and full-year guidance rose to $4.60-$4.75 billion.
  • Ziihera approval on August 25, 2026 opens a $3 billion-$5 billion peak-sales opportunity.
  • Zepzelca and Xywav posted strong 2026 growth, validating Jazz's oncology and sleep franchises.

What critics are saying

  • Lupin, Teva, and Tris challenge Xywav and Xyrem, threatening 2027-2033 economics.
  • Granules settled in March 2026 with launch rights under confidential terms, pressuring Xywav pricing.
  • Jazz took on Actio for $820 million upfront; ABS-1230 still faces clinical and regulatory failure.

What makes Jazz Pharmaceuticals unique

  • Xywav owns narcolepsy and idiopathic hypersomnia through FDA orphan exclusivity until July 2027.
  • Epidiolex gives Jazz rare epilepsy scale, with durable U.S. brand recognition since 2021 GW acquisition.
  • Ziihera launch on August 25, 2026 expands Jazz into HER2-positive gastroesophageal cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

0%
StockTitan
Aug 27th, 2026
Jazz Pharmaceuticals prices upsized $1.1B exchangeable notes offering with $225M share repurchase

Jazz Pharmaceuticals has priced an upsized $1.1 billion private offering of 1.875% exchangeable senior notes due 2032, up from the previously announced $1.0 billion. The offering, conducted through its wholly-owned subsidiary Jazz Investments I Limited, is expected to close on 31 August 2026. The notes will mature on 15 September 2032 and are exchangeable at an initial rate of 2.8150 ordinary shares per $1,000 principal amount, equivalent to an exchange price of approximately $355.24 per share. This represents a 42.5% premium above the last reported sale price on 26 August 2026. The company will use net proceeds of approximately $1,079 million for general corporate purposes. Concurrently, Jazz Pharmaceuticals agreed to repurchase approximately $225 million of its ordinary shares from note purchasers at $249.29 per share, using existing cash on hand.

Yahoo Finance
Aug 26th, 2026
Jazz Pharmaceuticals launches Ziihera for HER2-positive cancer with $3B–$5B peak sales outlook

Jazz Pharmaceuticals has launched Ziihera in the US following FDA approval for first-line treatment of HER2-positive, unresectable or metastatic gastroesophageal adenocarcinoma. The drug can be used with tislelizumab and chemotherapy, or with chemotherapy alone for certain patients. In the Phase III HERIZON-GEA-01 trial, Ziihera-based regimens reduced the risk of disease progression or death by 35%. The triplet regimen extended median overall survival to 26.4 months, a 28% reduction in death risk versus trastuzumab. Jazz estimates the US addressable market at 3,000–4,000 patients annually and raised Ziihera's peak sales outlook to $3 billion–$5 billion. The company plans to leverage existing commercial infrastructure whilst pursuing additional cancer indications and international regulatory filings.

Yahoo Finance
Aug 11th, 2026
Jazz Pharmaceuticals Q2 revenue beats estimates at $1.21B, ups guidance to $4.68B

Jazz Pharmaceuticals reported a strong second quarter with revenue of $1.21 billion, beating analyst estimates of $1.12 billion and representing 15.5% year-on-year growth. The company raised its full-year revenue guidance to $4.68 billion from $4.38 billion. CEO Renée Galá attributed the performance to strong demand for flagship products like Xywav and Epidiolex, alongside accelerating uptake of new oncology therapies. Operating margin improved to 20.5%, up from negative 65.6% in the prior year quarter. However, adjusted earnings per share of $5.71 missed analyst expectations of $6.18. During the earnings call, analysts focused on Epidiolex's growth drivers, Xywav's sustainability amid potential generic competition, and zanidatamab's upcoming approval prospects.

Yahoo Finance
Aug 11th, 2026
Jazz Pharma raises 2026 guidance on record Q2 revenue of $1.2B, up 16%

Jazz Pharmaceuticals reported record second quarter revenue of $1.2 billion, representing 16% year-over-year growth. The company raised its full-year revenue guidance based on strong first-half performance. Chief executive officer Renée Galá attributed the results to execution across the company's diversified portfolio and sustained demand for its commercial products. The company is preparing to launch zanidatamab, with a PDUFA date of 25 August for treatment of first-line HER2-positive metastatic gastroesophageal adenocarcinoma. The earnings call included updates from senior leadership, including chief commercial officer Samantha Pearce, global head of research and development Robert Iannone, and chief financial officer Philip Johnson. Jazz Pharmaceuticals highlighted progress on its long-term value creation priorities whilst maintaining focus on current commercial operations.

Yahoo Finance
Aug 10th, 2026
Jazz Pharmaceuticals to acquire Actio Biosciences for $820M upfront, adding KCNT1+ epilepsy therapy

Jazz Pharmaceuticals has agreed to acquire Actio Biosciences for $820 million upfront and up to $500 million in contingent payments. The deal adds ABS-1230, a clinical-stage precision therapy for KCNT1+ epilepsy, to Jazz's rare epilepsy portfolio. KCNT1+ epilepsy is a rare genetic condition affecting approximately 2,500 patients in the United States. Patients typically experience dozens to hundreds of seizures daily that resist standard medications. Around 80% of cases begin in infancy, with many children unable to reach basic developmental milestones. There are currently no FDA-approved therapies for KCNT1+ epilepsy. ABS-1230 recently showed meaningful seizure reductions in an early clinical trial. The ongoing Phase 1b/2a KYRON trial is designed as the registrational study supporting US new drug application submission.